US Stock MarketDetailed Quotes
CARA Cara Therapeutics
- 0.304
- +0.016+5.52%
Close Nov 29 13:00 ET
- 0.306
- +0.002+0.66%
Post 17:01 ET
16.68MMarket Cap-173P/E (TTM)
0.306High0.286Low108.41KVolume0.286Open0.288Pre Close32.09KTurnover0.23%Turnover RatioLossP/E (Static)54.86MShares1.31052wk High23.38P/B14.22MFloat Cap0.24052wk Low--Dividend TTM46.79MShs Float29.647Historical High--Div YieldTTM6.94%Amplitude0.240Historical Low0.296Avg Price1Lot Size
About Cara Therapeutics Company
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Company Profile
SymbolCARA
Company NameCara Therapeutics
Listing DateJan 31, 2014
Issue Price11.00
Founded2004
CEOMr. Christopher A. Posner
MarketNASDAQ
Employees55
Fiscal Year Ends12-31
Address400 Atlantic Street,Suite 500
CityStamford
ProvinceConnecticut
CountryUnited States of America
Zip Code06901
Phone1-203-406-3700
Company Executives
- Name
- Position
- Salary
- Christopher A. Posner
- President, Chief Executive Officer and Director
- 2.92M
- Ryan D. Maynard
- Chief Financial Officer and Principal Accounting Officer
- 1.24M
- Scott M. Terrillion
- General Counsel, Secretary and Chief Compliance Officer
- --
- Martin A. Vogelbaum
- Chairman of the Board
- 519.99K
- Dr. Lisa von Moltke, M.D.
- Independent Director
- 254.99K
- Dr. Jeffrey L. Ives, PhD
- Independent Director
- 272.49K
- Helen M. Boudreau, M.B.A.
- Independent Director
- 376.01K
- Dr. Susan Shiff, M.B.A.,PhD
- Independent Director
- 262.49K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data